The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit
Abstract
Many human cancers involve up-regulation of the phosphoinositide 3-kinase PI3Kα, with oncogenic mutations identified in both the p110α catalytic and the p85α regulatory subunits. We used crystallographic and biochemical approaches to gain insight into activating mutations in two noncatalytic p110α domains—the adaptor-binding and the helical domains. A structure of the adaptor-binding domain of p110α in a complex with the p85α inter–Src homology 2 (inter-SH2) domain shows that oncogenic mutations in the adaptor-binding domain are not at the inter-SH2 interface but in a polar surface patch that is a plausible docking site for other domains in the holo p110/p85 complex. We also examined helical domain mutations and found that the Glu 545 to Lys 545 (E545K) oncogenic mutant disrupts an inhibitory charge-charge interaction with the p85 N-terminal SH2 domain. These studies extend our understanding of the architecture of PI3Ks and provide insight into how two classes of mutations that cause a gain in function can lead to cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Synthesis and Function of 3-Phosphorylated Inositol Lipids
Vanhaesebroeck, B., Leevers, S. J., Ahmadi, K., Timms, J., Katso, R., Driscoll, P. C., Woscholski, R., Parker, P. J., & Waterfield, M. D. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.535 · Cited by 1,535
ConSurf 2005: the projection of evolutionary conservation scores of residues on protein structures
Landau, M., Mayrose, I., Rosenberg, Y., Glaser, F., Martz, E., Pupko, T., & Ben-Tal, N. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki370 · Cited by 1,413
Targeting the PI3K-Akt pathway in human cancer
Luo, J., Manning, B. D., & Cantley, L. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00248-4 · Cited by 1,290
Saal, L. H., Holm, K., Maurer, M., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., Mansukhani, M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 875
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
Kang, S., Bader, A. G., & Vogt, P. K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408864102 · Cited by 823
Oncogenic PI3K deregulates transcription and translation
Bader, A. G., Kang, S., Zhao, L., & Vogt, P. K. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1753 · Cited by 798
Yu, J., Zhang, Y., McIlroy, J., Rordorf-Nikolic, T., Orr, G. A., & Backer, J. M. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.3.1379 · Cited by 520
Self-citationBreast Cancer–Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells
Isakoff, S. J., Engelman, J. A., Irie, H. Y., Luo, J., Brachmann, S. M., Pearline, R. V., Cantley, L. C., & Brugge, J. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2612 · Cited by 509
Cited by
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
“In contrast, E542K and E545Kmutations disrupt the inhibitory interface with the N-SH2 domains of the regulatory subunits (Burke et al., 2012; Miled et al., 2007).”
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
PI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
The emerging mechanisms of isoform-specific PI3K signalling
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2882 · Cited by 1,767
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Phosphoinositides: Tiny Lipids With Giant Impact on Cell Regulation
Balla, T. (2013) · Physiological Reviews · doi:10.1152/physrev.00028.2012 · Cited by 1,638
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Thorpe, L. M., Yuzugullu, H., & Zhao, J. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3860 · Cited by 1,345
Wymann, M. P., & Schneiter, R. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2335 · Cited by 1,291
PTEN and the PI3-Kinase Pathway in Cancer
Chalhoub, N., & Baker, S. J. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092311 · Cited by 1,245
The PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
PI3K/AKT signaling pathway and cancer: An updated review
Martini, M., De Santis, M. C., Braccini, L., Gulluni, F., & Hirsch, E. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.912836 · Cited by 1,020
Zhong, Y., Wang, Q. J., Li, X., Yan, Y., Backer, J. M., Chait, B. T., Heintz, N., & Yue, Z. (2009) · Nature Cell Biology · doi:10.1038/ncb1854 · Cited by 1,005
Self-citationSubtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
Barretina, J., Taylor, B. S., Banerji, S., Ramos, A. H., Lagos-Quintana, M., DeCarolis, P. L., Shah, K., Socci, N. D., Weir, B. A., Ho, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.619 · Cited by 735
The regulation and function of Class III PI3Ks: novel roles for Vps34
Backer, J. M. (2008) · Biochemical Journal · doi:10.1042/bj20071427 · Cited by 659
Self-citationClass I PI3K in oncogenic cellular transformation
Zhao, L., & Vogt, P. K. (2008) · Oncogene · doi:10.1038/onc.2008.244 · Cited by 594
The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations
Huang, C.-H., Mandelker, D., Schmidt-Kittler, O., Samuels, Y., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., Gabelli, S. B., & Amzel, L. M. (2007) · Science · doi:10.1126/science.1150799 · Cited by 560
Targeting phosphoinositide 3-kinase—Moving towards therapy
Marone, R., Cmiljanovic, V., Giese, B., & Wymann, M. P. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.10.003 · Cited by 548
Eichhorn, P. J. A., Gili, M., Scaltriti, M., Serra, V., Guzman, M., Nijkamp, W., Beijersbergen, R. L., Valero, V., Seoane, J., Bernards, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1740 · Cited by 499
The pathogenic role of PI3K/AKT pathway in cancer onset and drug resistance: an updated review
Rascio, F., Spadaccino, F., Rocchetti, M. T., Castellano, G., Stallone, G., Netti, G. S., & Ranieri, E. (2021) · Cancers · doi:10.3390/cancers13163949 · Cited by 497
Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells
Okkenhaug, K. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095946 · Cited by 446
Zhao, L., & Vogt, P. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712169105 · Cited by 437
Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors
Millis, S. Z., Ikeda, S., Reddy, S., Gatalica, Z., & Kurzrock, R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0891 · Cited by 315
Papa, A., & Pandolfi, P. P. (2019) · Biomolecules · doi:10.3390/biom9040153 · Cited by 303
Burke, J. E., Perisic, O., Masson, G. R., Vadas, O., & Williams, R. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205508109 · Cited by 300
Self-citationStructural Basis for Activation and Inhibition of Class I Phosphoinositide 3-Kinases
Vadas, O., Burke, J. E., Zhang, X., Berndt, A., & Williams, R. L. (2011) · Science Signaling · doi:10.1126/scisignal.2002165 · Cited by 299
Self-citationEmerging common themes in regulation of PIKKs and PI3Ks
Lempiäinen, H., & Halazonetis, T. D. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.281 · Cited by 298
A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane
Mandelker, D., Gabelli, S. B., Schmidt-Kittler, O., Zhu, J., Cheong, I., Huang, C.-H., Kinzler, K. W., Vogelstein, B., & Amzel, L. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908444106 · Cited by 293
The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors
Berndt, A., Miller, S., Williams, O., Le, D. D., Houseman, B. T., Pacold, J. I., Gorrec, F., Hon, W.-C., Ren, P., Liu, Y., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.293 · Cited by 292
Self-citationSomatic Mutations in p85α Promote Tumorigenesis through Class IA PI3K Activation
Jaiswal, B. S., Janakiraman, V., Kljavin, N. M., Chaudhuri, S., Stern, H. M., Wang, W., Kan, Z., Dbouk, H. A., Peters, B. A., Waring, P., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.016 · Cited by 289
Self-citationAnnotating Cancer Variants and Anti-Cancer Therapeutics in Reactome
Milacic, M., Haw, R., Rothfels, K., Wu, G., Croft, D., Hermjakob, H., D'Eustachio, P., & Stein, L. (2012) · Cancers · doi:10.3390/cancers4041180 · Cited by 280
Structural Basis for Regulation of Phosphoinositide Kinases and Their Involvement in Human Disease
Burke, J. E. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.08.005 · Cited by 276
PI3K and AKT: Unfaithful Partners in Cancer
Faes, S., & Dormond, O. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160921138 · Cited by 274
O'Brien, C., Wallin, J. J., Sampath, D., GuhaThakurta, D., Savage, H., Punnoose, E. A., Guan, J., Berry, L., Prior, W. W., Amler, L. C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2828 · Cited by 255
Synergy in activating class I PI3Ks
Burke, J. E., & Williams, R. L. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.12.003 · Cited by 216
Self-citationPIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches
Ligresti, G., Militello, L., Steelman, L. S., Cavallaro, A., Basile, F., Nicoletti, F., Stivala, F., McCubrey, J. A., & Libra, M. (2009) · Cell Cycle · doi:10.4161/cc.8.9.8255 · Cited by 214
PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer
Crane, C. A., Panner, A., Murray, J. C., Wilson, S. P., Xu, H., Chen, L., Simko, J. P., Waldman, F. M., Pieper, R. O., & Parsa, A. T. (2009) · Oncogene · doi:10.1038/onc.2008.384 · Cited by 181
Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases
Hon, W.-C., Berndt, A., & Williams, R. L. (2012) · Oncogene · doi:10.1038/onc.2011.532 · Cited by 129
Self-citationBurke, J. E., & Williams, R. L. (2013) · Advances in Biological Regulation · doi:10.1016/j.jbior.2012.09.005 · Cited by 102
“In addition to stimulating PI3K in vitro (Miled et al., 2007; Burke et al., 2011; Zhang et al., 2011), this mutation is oncogenic in cells (Sun et al., 2010; Hofmann and Jücker, 2012).”
BackgroundInfluentialSelf-citationChakrabarty, A., Rexer, B. N., Wang, S. E., Cook, R. S., Engelman, J. A., & Arteaga, C. L. (2010) · Oncogene · doi:10.1038/onc.2010.257 · Cited by 102
Janmey, P. A., Bucki, R., & Radhakrishnan, R. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.07.155 · Cited by 101
Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway
Lou, H., Villagran, G., Boland, J. F., Im, K. M., Polo, S., Zhou, W., Odey, U., Juárez-Torres, E., Medina-Martínez, I., Roman-Basaure, E., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1837 · Cited by 88
Sudhan, D. R., Guerrero-Zotano, A., Won, H., González Ericsson, P., Servetto, A., Huerta-Rosario, M., Ye, D., Lee, K.-M., Formisano, L., Guo, Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.013 · Cited by 49
“The nSH2 and iSH2 domains of p85a interact with helical and C2 domains of p110α, respectively, to repress its catalytic function (Burke et al., 2012; Miled et al., 2007).”
Background
Metadata
- Authors
- Miled, N., Yan, Y., Hon, W.-C., Perisic, O., Zvelebil, M., Inbar, Y., Schneidman-Duhovny, D., Wolfson, H. J., Backer, J. M., & Williams, R. L.
- Venue
- Science
- Published
- 2007-07-13
- Volume
- 317
- Issue
- 5835
- Pages
- 239-242
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2054607545
- Cited by
- 410
- References
- 28
- FWCI
- 11.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.